Truvestments Capital’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Truvestments Capital’s Portfolio GBT Stock Details GBT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-300	Closed	-$20K	–	980
2022 Q3	$20K	Hold	300	–	–	0.01%	344
2022 Q2	$10K	Buy	+300	New	+$8.78K	0.01%	417
2022 Q1	–	Sell	-488	Closed	-$14K	–	608
2021 Q4	$14K	Hold	488	–	–	0.01%	375
2021 Q3	$12K	Hold	488	–	–	0.01%	363
2021 Q2	$17K	Sell	488 -375	-43%	-$14.6K	0.01%	347
2021 Q1	$35K	Sell	863 -62	-7%	-$2.85K	0.02%	316
2020 Q4	$40K	Buy	+925	New	+$45.6K	0.03%	290
2020 Q3	–	Sell	-925	Closed	-$58K	–	594
2020 Q2	$58K	Hold	925	–	–	0.06%	196
2020 Q1	$47K	Buy	+925	New	+$62K	0.06%	182
2019 Q4	–	Sell	-925	Closed	-$45K	–	654
2019 Q3	$45K	Buy	925 +300	+48%	+$15.6K	0.03%	281
2019 Q2	$33K	Hold	625	–	–	0.02%	338
2019 Q1	$33K	Buy	+625	New	+$30.7K	0.03%	335
2018 Q3	$25K	Buy	+658	New	+$29.1K	0.01%	482

Other funds holding GBT

BTI

Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Truvestments Capital's GBT Position: Q4 2022 in Review

Truvestments Capital sold out of Global Blood Therapeutics, Inc. (GBT) in Q4 2022, closing a stake of 300 shares — an estimated $20K sold.

Truvestments Capital first reported a position in GBT in Q3 2018 and held it in 13 quarters. The position peaked at $58K in Q2 2020. 2 funds tracked by Wall St. Rank hold GBT as of Q4 2022.

Truvestments Capital reported no remaining Global Blood Therapeutics, Inc. position as of Q4 2022 after selling out during the quarter.
Truvestments Capital sold 300 Global Blood Therapeutics, Inc. shares in Q4 2022, an estimated $20K.
Truvestments Capital first reported a position in Global Blood Therapeutics, Inc. in Q3 2018 and held it in 13 quarters.
Truvestments Capital's Global Blood Therapeutics, Inc. position peaked at $58K in Q2 2020.
2 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q4 2022.

Based on Truvestments Capital's 13F filing for Q4 2022, filed 14 Feb 2023.